Abstract
We present a case of progressive Mycobacterium chelonae ssp. chelonae necrotizing pneumonia after hematopoietic stem cell transplantation (HSCT) in the presence of chronic graft-versus-host disease. The patient failed to respond to standard combination therapy with multiple agents and developed resistance to most drugs over the course of treatment. Tigecycline, a new glycylcycline antimicrobial agent with in vitro activity against M. chelonae, was then used with a clinical response to treatment. To our knowledge, this is the first reported case demonstrating tigecycline to have a degree of clinical effectiveness to treat refractory pulmonary infection with M. chelonae in an HSCT recipient.
Original language | English (US) |
---|---|
Pages (from-to) | 57-63 |
Number of pages | 7 |
Journal | Transplant Infectious Disease |
Volume | 11 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2009 |
All Science Journal Classification (ASJC) codes
- Infectious Diseases
- Transplantation